High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients

• Published in: Hereditary Cancer in Clinical Practice
• Main Authors: Suspitsin Evgeny N, Sherina Nathalia, Ponomariova Daria N, Sokolenko Anna P, Iyevleva Aglaya G, Gorodnova Tatyana V, Zaitseva Olga A, Yatsuk Olga S, Togo Alexandr V, Tkachenko Nathalia N, Shiyanov Grigory A, Lobeiko Oksana S, Krylova Nadezhda, Matsko Dmitry E, Maximov Sergey, Urmancheyeva Adel F, Porhanova Nathalia V, Imyanitov Evgeny N
• Format: Article in Journal/Newspaper
• Language: English
• Published: BMC 2009
• Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282; Genetics; QH426-470; North-Western Russia
• Online Access: https://doi.org/10.1186/1897-4287-7-5; https://doaj.org/article/bdf87e8757ba49f0a03bbb28c435b737

Abstract Background A significant portion of ovarian cancer (OC) cases is caused by germ-line mutations in BRCA1 or BRCA2 genes. BRCA testing is cheap in populations with founder effect and therefore recommended for all patients with OC diagnosis. Recurrent mutations constitute the vast majority of BRCA defects in Russia, however their impact in OC morbidity has not been yet systematically studied. Furthermore, Russian population is characterized by a relatively high frequency of CHEK2 and NBS1 (NBN) heterozygotes, but it remains unclear whether these two genes contribute to the OC risk. Methods The study included 354 OC patients from 2 distinct, geographically remote regions (290 from North-Western Russia (St.-Petersburg) and 64 from the south of the country (Krasnodar)). DNA samples were tested by allele-specific PCR for the presence of 8 founder mutations (BRCA1 5382insC, BRCA1 4153delA, BRCA1 185delAG, BRCA1 300T>G, BRCA2 6174delT, CHEK2 1100delC, CHEK2 IVS2+1G>A, NBS1 657del5). In addition, literature data on the occurrence of BRCA1, BRCA2, CHEK2 and NBS1 mutations in non-selected ovarian cancer patients were reviewed. Results BRCA1 5382insC allele was detected in 28/290 (9.7%) OC cases from the North-West and 11/64 (17.2%) OC patients from the South of Russia. In addition, 4 BRCA1 185delAG, 2 BRCA1 4153delA, 1 BRCA2 6174delT, 2 CHEK2 1100delC and 1 NBS1 657del5 mutation were detected. 1 patient from Krasnodar was heterozygous for both BRCA1 5382insC and NBS1 657del5 variants. Conclusion Founder BRCA1 mutations, especially BRCA1 5382insC variant, are responsible for substantial share of OC morbidity in Russia, therefore DNA testing has to be considered for every OC patient of Russian origin. Taken together with literature data, this study does not support the contribution of CHEK2 in OC risk, while the role of NBS1 heterozygosity may require further clarification.